Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

NCT ID: NCT03742544

Last Updated: 2018-11-15

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 600 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-06-23
• Study Completion Date: 2020-10-30

Brief Summary

Post-marketing surveillance of Telostop TAB (Telmisartan/Rosuvastatin)

Detailed Description

Telostop TAB is fixed-dose combination of telmisartan and rosuvastatin, which was approved in 2015 in the Republic of Korea for the treatment of patients with hypertention and dyslipidemia. A post-marketing surveillance was conducted following the approval to obtain data on the safety and efficacy of Telostop TAB in real-world practice.

Conditions

Hypertension; Dyslipidemias

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• The patient who is first prescribed and administered Telostop plus Tab.

Exclusion Criteria

• The patients who are overreacting to this drug or its components
• The patients to the "Do not administer to the next patient" section of the approved instructions for use

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IlDong Pharmaceutical Co Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ID-TERO-401

Identifier Type: -

Identifier Source: org_study_id